Psoriatic Arthritis

Disease State Hub

Podcasts

Psoriatic Arthritis

Philip J. Mease, MD, on a New Interleukin Antagonist as Therapy for Psoriatic Arthritis

09/12/2019

Philip J. Mease, MD, from Swedish Medical Center, discusses his research on an anti-interleukin-23p19 monoclonal antibody that may be a potential therapeutic option for the treatment of psoriatic...

09/12/2019

Psoriatic Arthritis

Philip J. Mease, MD, on a New Interleukin Antagonist as Therapy for Psoriatic Arthritis

09/12/2019

Philip J. Mease, MD, from Swedish Medical Center, discusses his research on an anti-interleukin-23p19 monoclonal antibody that may be a potential therapeutic option for the treatment of psoriatic...

09/12/2019

Research Summaries

FDA ALERT

FDA ALERT

FDA Approves Interchangeable Biosimilar for Psoriatic Arthritis, Other Inflammatory Conditions

11/30/2023

Anthony Calabro, MA

The FDA approved ustekinumab-auub as an interchangeable biosimilar with ustekinumab for multiple inflammatory diseases.

11/30/2023

research summary

research summary

Drug Survival, Effectiveness of IL-23 Inhibitors for Psoriasis, PsA

10/26/2023

Leigh Precopio

Despite being approved for use, consensus among the real-world data on the use of IL-23 inhibitors in psoriatic disease has been lacking; therefore, researchers recently examined the drug survival and...

10/26/2023

Research summary

Can a Novel Tool Predict the Risk of Developing Psoriatic Arthritis Among Those With Psoriasis?

10/13/2023

Anthony Calabro, MA

Researchers aimed to develop a risk prediction model for psoriatic arthritis progression in patients with psoriasis.

10/13/2023

research summary

research summary

High Comorbidities, Risk Factors in Early PsA

09/21/2023

Leigh Precopio

In a recent study, researchers examined the prevalence of comorbidities and risk factors in individuals with newly diagnosed psoriatic arthritis.

09/21/2023

Research Summary

Male, Female Patients With Psoriatic Arthritis Treated With Tofacitinib Show Similar Responses, Key Differences

08/16/2023

Anthony Calabro, MA

In a post hoc analysis of two phase 3 trials, researchers set out to determine the impact of sex on tofacitinib in terms of efficacy, safety, and time to discontinuation.

08/16/2023

April 2026

Current Issue

April 2026